Exploring the potential for Viking Therapeutics' VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Executed on:Jul 19, 2024 3:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Imperial College LondonConsultant Hepatologist at Imperial College Healthcare NHS Trust, and Honorary Senior Lecturer at Imperial College London.
Leads the NAFLD service in the Trust, overseeing a clinic that cares for more than 600 patients.
Research interests are focused in translational aspects of NAFLD care, including prediction of cardiovascular risk, quantitation of liver biopsies from NAFLD patients using machine learning, and management of NAFLD cirrhosis. 

Interview Goal

This call will focus on the recently announced positive 52 week data from the Phase 2b VOYAGE Study of VK2809 by Viking Therapeutics showing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.